Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition

PURPOSE: Targeted cancer therapeutics have not significantly benefited patients with Ewing sarcoma with metastatic or relapsed disease. Understanding the molecular underpinnings of drug resistance can lead to biomarker-driven treatment selection. EXPERIMENTAL DESIGN: Receptor tyrosine kinase (RTK) p...

Descripción completa

Detalles Bibliográficos
Autores principales: Soni, Upendra Kumar, Wang, Yuhua, Pandey, Ram Naresh, Roberts, Ryan, Pressey, Joseph G., Hegde, Rashmi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843438/
https://www.ncbi.nlm.nih.gov/pubmed/36394520
http://dx.doi.org/10.1158/1078-0432.CCR-22-2587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843438/
https://www.ncbi.nlm.nih.gov/pubmed/36394520
http://dx.doi.org/10.1158/1078-0432.CCR-22-2587

Ejemplares similares